Molecular profile in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta-analysis

Clinical and Translational Oncology Pub Date : 2024-04-05 DOI:10.1007/s12094-024-03401-y

Ana Luzarraga Aznar, Vicente Bebia, Natalia Rodriguez Gomez-Hidalgo, Carlos López-Gil, Marta Miguez, Eva Colas, Asunción Pérez-Benavente, Antonio Gil-Moreno, Silvia Cabrera

{"title":"Molecular profile in endometrial carcinoma: can we predict the lymph node status? A systematic review and meta-analysis","authors":"Ana Luzarraga Aznar, Vicente Bebia, Natalia Rodriguez Gomez-Hidalgo, Carlos López-Gil, Marta Miguez, Eva Colas, Asunción Pérez-Benavente, Antonio Gil-Moreno, Silvia Cabrera","doi":"10.1007/s12094-024-03401-y","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Molecular classification of endometrial cancer (EC) has become a promising information to tailor preoperatively the surgical treatment. We aimed to evaluate the rate of lymph node metastases (LNM) in patients with EC according to molecular profile.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A systematic review and meta-analysis were performed according to PRISMA guidelines by searching in two major electronic databases (PubMed and Scopus), including original articles reporting lymph node metastases according to the molecular classification of EC as categorized in the ESGO-ESMO-ESP guidelines.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Fifteen studies enrolling 3056 patients were included. Pooled prevalence LNM when considering only patients undergoing lymph node assessment was 4% for POLE-mutated (95%CI: 0-12%), 22% for no specific molecular profile (95% CI: 9-39%), 23% for Mismatch repair-deficiency (95%CI: 10-40%) and 31% for p53-abnormal (95%CI: 24-39%).</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>The presence of LNM seems to be influenced by molecular\nclassification. P53-abnormal group presents the highest rate of nodal involvement, and POLE-mutated the lowest.</p>","PeriodicalId":10166,"journal":{"name":"Clinical and Translational Oncology","volume":"95 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12094-024-03401-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Molecular classification of endometrial cancer (EC) has become a promising information to tailor preoperatively the surgical treatment. We aimed to evaluate the rate of lymph node metastases (LNM) in patients with EC according to molecular profile.

Methods

A systematic review and meta-analysis were performed according to PRISMA guidelines by searching in two major electronic databases (PubMed and Scopus), including original articles reporting lymph node metastases according to the molecular classification of EC as categorized in the ESGO-ESMO-ESP guidelines.

Results

Fifteen studies enrolling 3056 patients were included. Pooled prevalence LNM when considering only patients undergoing lymph node assessment was 4% for POLE-mutated (95%CI: 0-12%), 22% for no specific molecular profile (95% CI: 9-39%), 23% for Mismatch repair-deficiency (95%CI: 10-40%) and 31% for p53-abnormal (95%CI: 24-39%).

Conclusions

The presence of LNM seems to be influenced by molecular classification. P53-abnormal group presents the highest rate of nodal involvement, and POLE-mutated the lowest.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

子宫内膜癌的分子谱：我们能否预测淋巴结状态？系统回顾与荟萃分析

目的子宫内膜癌（EC）的分子分类已成为术前调整手术治疗的有效信息。方法根据PRISMA指南，在两大电子数据库（PubMed和Scopus）中进行检索，包括根据ESGO-ESMO-ESP指南中的EC分子分类报告淋巴结转移的原始文章。当仅考虑接受淋巴结评估的患者时，POLE突变型患者的LNM发生率为4%（95%CI：0-12%），无特定分子特征的患者为22%（95%CI：9-39%），错配修复缺陷型患者为23%（95%CI：10-40%），p53正常型患者为31%（95%CI：24-39%）。P53正常组结节受累率最高，POLE突变组最低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and Translational Oncology

自引率

0.00%

发文量